NewEdge Advisors’s Cardiol Therapeutics CRDL Stock Holding History

NewEdge Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$4.77K	–	4196
2025 Q4	$4.77K	Buy	+5,000	New	+$5.24K	﹤0.01%	3698

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NewEdge Advisors's CRDL Position: Q1 2026 in Review

NewEdge Advisors sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 5,000 shares — an estimated $4.77K sold.

NewEdge Advisors first reported a position in CRDL in Q4 2025 and held it in 1 quarter. The position peaked at $4.77K in Q4 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

NewEdge Advisors reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 5,000 Cardiol Therapeutics shares in Q1 2026, an estimated $4.77K.
NewEdge Advisors first reported a position in Cardiol Therapeutics in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's Cardiol Therapeutics position peaked at $4.77K in Q4 2025.
47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.